UBR7 and neoplasm: The evidence from this study showing silencing of UBR7 mitigates tumor formation from both GSI sensitive and resistant T-ALL cell lines, opens a new therapeutic window and suggest future efforts should be directed towards developing clinical inhibitors against UBR7.